Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lutz

Showing results (51-60 of 119) with videos related to

Pageof 12
Sort By:
Frontiers in Microbiology|October 5, 2020
Protein Domain Guided Screen for Sequence Specific and Phosphorothioate-Dependent Restriction EndonucleasesThomas Lutz, Honorata Czapinska, Alexey Fomenkov, et al.
Infection|May 5, 2016
Efficacy of two antiseptic regimens on skin colonization of insertion sites for two different catheter types: a randomized, clinical trialJuergen Thomas Lutz, Isabel Victoria Diener, Kerstin Freiberg, et al.
European Journal of Gastroenterology & Hepatology|June 12, 2013
Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practiceClaus Niederau, Stefan Mauss, Klaus Böker, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Trials|May 24, 2017
Laparoscopic Roux-en-Y gastric bypass versus laparoscopic mini gastric bypass in the treatment of obesity: study protocol for a randomized controlled trialMarko Kraljević, Tarik Delko, Thomas Köstler, et al.
Journal of the International AIDS Society|November 15, 2014
144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohortEva Wolf, Andreas Trein, Axel Baumgarten, et al.
Journal of Viral Hepatitis|July 21, 2021
Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-RegistryJenny Bischoff, Stefan Mauss, Thomas Lutz, et al.
Viruses|July 27, 2022
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)Markus Cornberg, Albrecht Stoehr, Uwe Naumann, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyMarkus Bickel, Stephan Zangos, Thomas Lutz, et al.
Open Forum Infectious Diseases|September 27, 2017
Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus CoinfectionChristoph Boesecke, Patrick Ingiliz, Florian Berger, et al.
Pageof 12

Showing results (51-60 of 119) with videos related to

Sort By:
Pageof 12
Frontiers in Microbiology|October 5, 2020
Protein Domain Guided Screen for Sequence Specific and Phosphorothioate-Dependent Restriction EndonucleasesThomas Lutz, Honorata Czapinska, Alexey Fomenkov, et al.
Infection|May 5, 2016
Efficacy of two antiseptic regimens on skin colonization of insertion sites for two different catheter types: a randomized, clinical trialJuergen Thomas Lutz, Isabel Victoria Diener, Kerstin Freiberg, et al.
European Journal of Gastroenterology & Hepatology|June 12, 2013
Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practiceClaus Niederau, Stefan Mauss, Klaus Böker, et al.
AIDS (London, England)|April 20, 2004
Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavirChristoph Stephan, Nils von Hentig, Irene Kourbeti, et al.
Trials|May 24, 2017
Laparoscopic Roux-en-Y gastric bypass versus laparoscopic mini gastric bypass in the treatment of obesity: study protocol for a randomized controlled trialMarko Kraljević, Tarik Delko, Thomas Köstler, et al.
Journal of the International AIDS Society|November 15, 2014
144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohortEva Wolf, Andreas Trein, Axel Baumgarten, et al.
Journal of Viral Hepatitis|July 21, 2021
Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-RegistryJenny Bischoff, Stefan Mauss, Thomas Lutz, et al.
Viruses|July 27, 2022
Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R)Markus Cornberg, Albrecht Stoehr, Uwe Naumann, et al.
Scandinavian Journal of Infectious Diseases|September 14, 2007
Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophyMarkus Bickel, Stephan Zangos, Thomas Lutz, et al.
Open Forum Infectious Diseases|September 27, 2017
Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus CoinfectionChristoph Boesecke, Patrick Ingiliz, Florian Berger, et al.
Pageof 12